QNRX — Quoin Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $0.10m
- -$11.03m
- 23
- 60
- 15
- 24
Annual income statement for Quoin Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 20-F | 20-F | 10-K | 10-K | 10-K |
| Standards: | IFRS | USG | USG | USG | USG |
| Status: | fx Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 4.07 | 6.06 | 8.84 | 9.38 | 9.53 |
| Operating Profit | -4.07 | -6.06 | -8.84 | -9.38 | -9.53 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -5.26 | -21.5 | -9.38 | -8.69 | -8.96 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -5.26 | -21.5 | -9.38 | -8.69 | -8.96 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -5.26 | -21.5 | -9.38 | -8.69 | -8.96 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -5.26 | -21.5 | -9.45 | -8.69 | -8.96 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -29,999 | -0.014 | -0 | -9.64 | -1.91 |